Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials

Analysis (n=6485) found in patients without a contraindication, rifampicin is likely to be the safest latent tuberculosis infection treatment option and safer than isoniazid.

Source: Current Awareness Service for Health (CASH) - January 3, 2020 Category: Consumer Health News Source Type: news